EXTROVIS is an integrated pharmaceutical company headquartered in Switzerland focusing on the development and manufacturing of niche and differentiated finished dose pharmaceutical products. A great number of our products are backward integrated with our in-house API for the long-term cost competitiveness and supply chain security.
Our Indian entity, Extrovis Private Limited in Hyderabad employs close to 60 scientists who develop our APIs and finished dosage form pharmaceuticals based on a cross-functional approach.
The newly established Extrovis EU, based in Hungary is besides being our bridgehead to the European market serves as supply chain, regulatory, pharmacovigilance and customer service hub for the regulated markets.
Our portfolio is a leveraged between all major geographies and comprises of both below the radar generic products and products with formulation improvements (i.e., lyo-to-liquid conversion) as well as products that have been fundamentally redesigned to improve efficacy, safety, patient convenience and compliance (i.e., drug-device combinations).